Type 2 diabetes treatment improvement after introduction of extended release tablets of glipizide, Glibenese GITS

Abstract

GITS system gives us unique pharmacokinetic and pharmacodynamic properties. Thanks to GITS it is possible to use short acting glipizide only once a day. Summing up results of performed studies, the introduction of Glibenese GITS into treatment of type 2 diabetes causes: 1) stable concentration of the drug in blood plasma over 24 hours; 2) decreased insulin secretion, necessary for the hypoglycaemic effect, when compared with other sulfonylureas; 3) decreased C-peptide secretion, when compared with other sulfonylureas; 4) decreased hepatic glucose production; 5) significant improvement of metabolic control, when compared to other sulfonylureas; 6) significant improvement of insulin sensitivity; 7) improvement of lipid metabolism; 8) possibility of equally efficient treatment in both younger and older patients; 9) possibility of equally efficient treatment in patients with mild chronic renal failure; 10) decreased risk of hypoglycaemia; 11) improvement of quality of life in type 2 diabetes. Glibenese is a single oral drug which was shown to improve the quality of life in type 2 diabetes. In summary, the Glibenese GITS, generated using the GITS technology, has unique advantages, which might or even should be used in the treatment of type 2 diabetes. Having considered numerous advantages and few disadvantages of the presented drug, we should think about Glibenese GITS, when we start or change the treatment of the type 2 diabetes.